{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:49:24Z","timestamp":1790660964753,"version":"4.1.0"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T00:00:00Z","timestamp":1471824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0159477","type":"journal-article","created":{"date-parts":[[2016,8,22]],"date-time":"2016-08-22T16:03:02Z","timestamp":1471881782000},"page":"e0159477","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":59,"title":["Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-4115","authenticated-orcid":true,"given":"Radhika","family":"Thokala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Olivares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejuan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourindra","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew","family":"Deniger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Torikai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Laskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence J. N.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,8,22]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.tibtech.2014.06.007","article-title":"Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells","volume":"32","author":"LJ Eggermont","year":"2015","journal-title":"Trends in Biotechnology"},{"issue":"6230","key":"ref2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"SA Rosenberg","year":"2015","journal-title":"Science"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1158\/2159-8290.CD-14-0477","article-title":"Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer","volume":"4","author":"JA Wargo","year":"2014","journal-title":"Cancer Discovery"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Z Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"22","key":"ref5","doi-asserted-by":"crossref","first-page":"10995","DOI":"10.1158\/0008-5472.CAN-06-0160","article-title":"CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells","volume":"66","author":"CM Kowolik","year":"2006","journal-title":"Cancer Res"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1172\/JCI46110","article-title":"CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients","volume":"121","author":"B Savoldo","year":"2011","journal-title":"J Clin Invest"},{"issue":"8","key":"ref7","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"MC Milone","year":"2009","journal-title":"Mol Ther"},{"issue":"7","key":"ref8","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.4049\/jimmunol.179.7.4910","article-title":"4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy","volume":"179","author":"H Zhang","year":"2007","journal-title":"J Immunol"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"XS Zhong","year":"2010","journal-title":"Mol Ther"},{"issue":"20","key":"ref10","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"JN Kochenderfer","year":"2010","journal-title":"Blood"},{"issue":"16","key":"ref11","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"SL Maude","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"303","key":"ref12","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"DL Porter","year":"2015","journal-title":"Science Translational Medicine"},{"key":"ref13","article-title":"Redirecting T cell specificity to EGFR using mRNA to self-limit expresssion of chimeric antigen receptor","author":"HG TH Caruso","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","volume":"118","author":"C Berger","year":"2008","journal-title":"J Clin Invest"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"L Gattinoni","year":"2011","journal-title":"Nat Med"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood-2010-05-286286","article-title":"Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy","volume":"117","author":"CS Hinrichs","year":"2011","journal-title":"Blood"},{"issue":"18","key":"ref17","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"RJ Brentjens","year":"2011","journal-title":"Blood"},{"issue":"16","key":"ref18","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"SA Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"ref19","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1182\/blood-2010-01-043737","article-title":"Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor","volume":"116","author":"B Jena","year":"2010","journal-title":"Blood"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jcyt.2014.12.009","article-title":"Early exposure to interleukin-21 limits rapidly generated anti-Epstein-Barr virus T-cell line differentiation","volume":"17","author":"J Orio","year":"2015","journal-title":"Cytotherapy"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors","volume":"121","author":"N Cieri","year":"2013","journal-title":"Blood"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mt.2010.31","article-title":"Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial","volume":"18","author":"R Brentjens","year":"2010","journal-title":"Mol Ther"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3390\/ph8020230","article-title":"Seatbelts in CAR therapy: How Safe Are CARS?","volume":"8","author":"K Minagawa","year":"2015","journal-title":"Pharmaceuticals"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2","volume":"18","author":"RA Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"15","key":"ref25","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1182\/blood-2013-09-529537","article-title":"Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells","volume":"123","author":"S Gill","year":"2014","journal-title":"Blood"},{"issue":"177","key":"ref26","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia","volume":"5","author":"RJ Brentjens","year":"2013","journal-title":"Science Translational Medicine"},{"issue":"224","key":"ref27","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"ML Davila","year":"2014","journal-title":"Sci Transl Med"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma","volume":"373","author":"AL Garfall","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"95","key":"ref29","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"M Kalos","year":"2011","journal-title":"Sci Transl Med"},{"issue":"9967","key":"ref30","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"DW Lee","year":"2015","journal-title":"The Lancet"},{"issue":"8","key":"ref31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"DL Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"ref32","unstructured":"SEER Stat Fact Sheets: Acute Myeloid Leukemia (AML): seer.cancer.gov; 2015 [cited 2015 10\/10\/2015]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\" xlink:type=\"simple\">http:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html<\/ext-link>."},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"H Dohner","year":"2010","journal-title":"Blood"},{"key":"ref34","article-title":"Update on Optimal Management of Acute Myeloid Leukemia","volume":"7","author":"FE Rassi","year":"2013","journal-title":"Clinical Medicine Insights: Oncology"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1097-0142(20010715)92:2<406::AID-CNCR1336>3.0.CO;2-U","article-title":"Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation","volume":"92","author":"FJ Giles","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1182\/blood-2003-01-0255","article-title":"Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation","volume":"102","author":"M Wadleigh","year":"2003","journal-title":"Blood"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1309\/AJCPO4DS0GTLSOEI","article-title":"Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors (&quot;hematogones&quot;) and B lymphoblastic leukemia blasts","volume":"132","author":"NM Hassanein","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"10","key":"ref38","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"CT Jordan","year":"2000","journal-title":"Leukemia"},{"issue":"12","key":"ref39","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"L Munoz","year":"2001","journal-title":"Haematologica"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"U Testa","year":"2014","journal-title":"Biomark Res"},{"issue":"8","key":"ref41","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2002-03-0852","article-title":"Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis","volume":"100","author":"U Testa","year":"2002","journal-title":"Blood"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/10428190701799035","article-title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","volume":"49","author":"A Frankel","year":"2008","journal-title":"Leukemia & lymphoma"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2014-04-566737","article-title":"Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients","volume":"124","author":"AE Frankel","year":"2014","journal-title":"Blood"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Roberts AW, He SZ, Bradstock FK, Hertzberg MS, Durrant STS, Ritchie D, et al. A Phase 1 and Correlative Biological Study of CSL360 (anti-CD123 mAb) in AML. Annual Meeting of the American Society of Hematology; San Francisco, CA2008.","DOI":"10.1182\/blood.V112.11.2956.2956"},{"issue":"21","key":"ref45","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood.V124.21.966.966","article-title":"Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies","volume":"124","author":"M Ruella","year":"2014","journal-title":"Blood"},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1158\/0008-5472.CAN-10-3843","article-title":"Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies","volume":"71","author":"H Singh","year":"2011","journal-title":"Cancer Res"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/imr.12137","article-title":"A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19","volume":"257","author":"H Singh","year":"2014","journal-title":"Immunol Rev"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1158\/0008-5472.CAN-07-5600","article-title":"Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system","volume":"68","author":"H Singh","year":"2008","journal-title":"Cancer Res"},{"issue":"6","key":"ref49","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/CJI.0b013e318053ed8e","article-title":"New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells","volume":"30","author":"X Du","year":"2007","journal-title":"J Immunother"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"14053","DOI":"10.1038\/mtm.2014.53","article-title":"Development of an inducible caspase-9 safety switch for pluripotent stem cell\u2013based therapies","volume":"1","author":"C Wu","year":"2014","journal-title":"Molecular Therapy\u2014Methods & Clinical Development"},{"key":"ref51","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","author":"X Zhou","year":"2015","journal-title":"Blood"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1073\/pnas.0811426106","article-title":"Reprogramming of murine and human somatic cells using a single polycistronic vector","volume":"106","author":"BW Carey","year":"2009","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"e0128151","DOI":"10.1371\/journal.pone.0128151","article-title":"Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations","volume":"10","author":"DC Deniger","year":"2015","journal-title":"PloS one"},{"issue":"5","key":"ref54","doi-asserted-by":"crossref","first-page":"e64138","DOI":"10.1371\/journal.pone.0064138","article-title":"Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells","volume":"8","author":"H Singh","year":"2013","journal-title":"PloS one"},{"issue":"5","key":"ref55","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/mt.sj.6300134","article-title":"Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules","volume":"15","author":"MM Suhoski","year":"2007","journal-title":"Mol Ther"},{"issue":"72","key":"ref56","first-page":"e50070","article-title":"Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood","author":"MH Huls","year":"2013","journal-title":"Journal of Visualized Experiments"},{"issue":"2","key":"ref57","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/cgt.2014.69","article-title":"Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor","volume":"22","author":"H Singh","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"ref58","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/gt.2011.40","article-title":"The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor","volume":"18","author":"Z Jin","year":"2011","journal-title":"Gene Ther"},{"issue":"29","key":"ref59","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"PR Kumaresan","year":"2014","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/mt.2012.267","article-title":"Bispecific T-cells expressing polyclonal repertoire of endogenous gammadelta T-cell receptors and introduced CD19-specific chimeric antigen receptor","volume":"21","author":"DC Deniger","year":"2013","journal-title":"Mol Ther"},{"issue":"22","key":"ref61","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-13-3451","article-title":"Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies","volume":"20","author":"DC Deniger","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"38","key":"ref62","doi-asserted-by":"crossref","first-page":"14342","DOI":"10.1073\/pnas.0804105105","article-title":"Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer","volume":"105","author":"BA Rabinovich","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"ref63","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1016\/j.bmc.2011.07.062","article-title":"Fluorinated cannabinoid CB2 receptor ligands: synthesis and in vitro binding characteristics of 2-oxoquinoline derivatives","volume":"19","author":"N Turkman","year":"2011","journal-title":"Bioorganic & medicinal chemistry"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4939-2727-2_6","article-title":"iCaspase 9 Suicide Gene System","volume":"1317","author":"X Zhou","year":"2015","journal-title":"Methods Mol Biol"},{"issue":"20","key":"ref65","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1158\/1078-0432.CCR-04-0322","article-title":"Heteroclitic CD33 peptide with enhanced anti-acute myeloid leukemic immunogenicity","volume":"10","author":"J Bae","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref66","first-page":"1730","article-title":"A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors","volume":"62","author":"M Feuring-Buske","year":"2002","journal-title":"Cancer Res"},{"issue":"11","key":"ref67","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1182\/blood.V93.11.3678","article-title":"Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate","volume":"93","author":"EL Sievers","year":"1999","journal-title":"Blood"},{"issue":"12","key":"ref68","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","article-title":"Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells","volume":"19","author":"M Hudecek","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ref69","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.4049\/jimmunol.180.10.7028","article-title":"Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane","volume":"180","author":"SE James","year":"2008","journal-title":"J Immunol"},{"issue":"18","key":"ref70","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1182\/blood-2012-12-474056","article-title":"T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia","volume":"122","author":"A Mardiros","year":"2013","journal-title":"Blood"},{"issue":"4","key":"ref71","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/mt.2014.208","article-title":"Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy","volume":"23","author":"M Jonnalagadda","year":"2015","journal-title":"Mol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0159477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T08:03:29Z","timestamp":1601021009000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0159477"}},"subtitle":[],"editor":[{"given":"Derya","family":"Unutmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,22]]},"references-count":71,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2016,8,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0159477","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,22]]}}}